Australian Operations
Include All CSL Sites

Seqirus and Italfarmaco announce partnership to bring amyotrophic lateral sclerosis product to Australia and New Zealand

Melbourne, Australia — 31-05-2017

  • Partnership grants Seqirus exclusive rights to commercialise Italfarmaco’s amyotrophic lateral sclerosis product in Australia and New Zealand.
  • Partnership reinforces Italfarmaco commitment to developing and bringing innovative central nervous system (CNS) options to patients.

Seqirus and Italfarmaco announce a long-term partnership in Australia and New Zealand for Italfarmaco’s product for the treatment of amyotrophic lateral sclerosis, the most common form of motor-neurone disease.

Under the new partnership Italfarmaco, through its subsidiary ITF Medilab Farma, will be responsible for product supply and Seqirus will undertake local registration and commercialisation of the product.

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a rare and devastating neurological disease. It is a progressive condition that can strike anyone and is ultimately fatal, with an average life-expectancy of 2 to 3 years after diagnosis. People with ALS progressively lose their ability to use their limbs and to speak, swallow and breathe, while in most cases the senses are not affected.1

The collaboration with Italfarmaco consolidates Seqirus’ position of being a leading in-licensing partner in the Australian and New Zealand market. “We recognise that access to more therapeutic options is very important to Australian healthcare professionals and sufferers of this devastating condition,” said Seqirus’ VP Commercial Operations, Dr Lorna Meldrum.

“We are delighted to work with Italfarmaco for the distribution, marketing and sales of their ALS product which is an important addition to Seqirus’ growing product range and further strengthens our broad portfolio of in-licensed medicines in Australia,” she said.

Francesco De Santis, President of Italfarmaco said “Expanding the reach of Italfarmaco’s products by entering new growth markets is an important part of our strategy. Seqirus is an attractive partner being a large local pharmaceutical company in Australia with a prominent track record in neurology. Australia and New Zealand are markets with resilient economies, substantial disease prevalence and established ALS markets.”

About amyotrophic lateral sclerosis (ALS)

ALS is the most common form of motor neurone disease. The effects of motor neurone disease and pattern of progression and survival time vary. The causes of the majority of cases of MND remain unknown. However about 5 to 10% of cases are inherited (familial) and the genetic fault of about 60% of these cases is now known in Australian families. There is currently no cure for MND however management of earlier symptoms may affect the disease progression.

Download This Release

PDF icon Seqirus and Italfarmaco announce partnership to bring amyotrophic lateral sclerosis product to Australia and New Zealand

About Seqirus

Seqirus is the new global company created from the combined strength and expertise of bioCSL and the influenza vaccines business formerly owned by Novartis. In July 2015, bioCSL and the influenza vaccines of Novartis joined forces to create Seqirus, now the second largest influenza business in the world. With the extensive research and production expertise and manufacturing plants in US, UK, and Australia, Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention of control of influenza globally. Seqirus has a workforce of over 2000 employees, significant manufacturing capacity and a presence in 20 countries.

Media Contacts:

Melanie Kerin
Senior Manager, Communications
Seqirus Australia
Phone: 03 9389 3486 Mobile: + 61 417 436 329


1MND Australia Fact Sheet

LinkedIn Twitter Facebook Google+
© 2018 Seqirus